CVA
MCID: CRB039
MIFTS: 67

Cerebrovascular Disease (CVA)

Categories: Blood diseases, Cardiovascular diseases, Neuronal diseases

Aliases & Classifications for Cerebrovascular Disease

MalaCards integrated aliases for Cerebrovascular Disease:

Name: Cerebrovascular Disease 12 55 15
Cerebrovascular Disorders 44 73
Cerebrovascular Accident 12 73
Stroke 12 44
Cerebrovascular Disorder 12
Cva 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6713
NCIt 50 C2938 C3390
SNOMED-CT 68 62914000 82797006

Summaries for Cerebrovascular Disease

Disease Ontology : 12 An vascular disease that is characterized by dysfunction of the blood vessels supplying the brain.

MalaCards based summary : Cerebrovascular Disease, also known as cerebrovascular disorders, is related to peripheral artery disease and stroke, ischemic, and has symptoms including seizures, tremor and angina pectoris. An important gene associated with Cerebrovascular Disease is HOTAIR (HOX Transcript Antisense RNA), and among its related pathways/superpathways are Metabolism of water-soluble vitamins and cofactors and Microglia Activation During Neuroinflammation: Overview. The drugs Rivastigmine and Amiloride have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and endothelial, and related phenotypes are Decreased free cholesterol and Increased LDL uptake

Wikipedia : 76 Cerebrovascular disease includes a variety of medical conditions that affect the blood vessels of the... more...

Related Diseases for Cerebrovascular Disease

Diseases related to Cerebrovascular Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1333)
# Related Disease Score Top Affiliating Genes
1 peripheral artery disease 32.3 ACE APOB CRP SELP
2 stroke, ischemic 32.3 ACE AGTR1 APOB APOE CRP MTHFR
3 vascular dementia 32.2 ACE ACHE APOE APP MTHFR NOTCH3
4 atherosclerosis susceptibility 32.1 APOA1 APOB APOE CRP PON1
5 cerebral palsy 32.0 APOE COL4A1 MTHFR
6 binswanger's disease 31.9 ACHE APOE APP NOTCH3
7 grange syndrome 31.9 CBS MTHFR PLAT SELP
8 supranuclear palsy, progressive, 1 31.8 ACHE APOE APP CBS
9 hypertension, essential 31.4 ACE ADM AGTR1 APOA1 APOB CRP
10 arteriosclerosis 31.4 ACE ADM APOA1 APOB APOE CRP
11 nervous system disease 31.2 ACE ACHE APOE APP CRP PLAT
12 cerebral atherosclerosis 31.2 ACE APOA1 APOE MTHFR
13 body mass index quantitative trait locus 11 31.2 APOA1 APOB APOE CRP PON1
14 dementia 31.1 ACHE APOE APP NOTCH3
15 sleep apnea 30.7 ACE APOE CRP
16 pulmonary embolism 30.6 CRP MTHFR PLAT
17 aortic atherosclerosis 30.4 ACE APOE PON1
18 ischemic heart disease 30.4 ACE APOA1 APOB APOE CRP MTHFR
19 arteries, anomalies of 30.3 ACE AGTR1 APOA1 APOB APOE CRP
20 homocystinuria 30.2 CBS MTHFR MTR
21 coronary artery anomaly 30.2 ACE AGTR1 APOA1 APOB CRP PLAT
22 carotid stenosis 30.2 ACE APOE CRP MTHFR SELP
23 ischemia 30.2 ACE APP PLAT PON1 SELP
24 atrial fibrillation 30.2 ACE AGTR1 CRP PLAT SELP
25 platelet aggregation, spontaneous 30.2 PLAT SELP
26 cerebral hemorrhage 30.2 APOB APP
27 ischemic optic neuropathy 30.1 ACE AGTR1 MTHFR
28 carotid artery disease 30.1 ACE APOA1 APOB APOE CRP
29 homocysteinemia 30.1 CBS CRP MTHFR MTR
30 hemorrhage, intracerebral 30.1 ACE APOE APP COL4A1 PLAT
31 angina pectoris 30.1 ACE CRP PLAT
32 lipid metabolism disorder 30.1 ACE APOA1 APOB APOE CRP
33 vitamin b12 deficiency 30.0 MTHFR MTR PON1
34 nonarteritic anterior ischemic optic neuropathy 30.0 ACE AGTR1 MTHFR
35 intermittent claudication 30.0 ACE CRP SELP
36 coronary heart disease 1 30.0 ACE AGTR1 APOA1 APOB APOE CRP
37 renovascular hypertension 30.0 ACE ADM AGTR1
38 end stage renal failure 30.0 ACE AGTR1 APOB CRP
39 carotid artery dissection 30.0 HOTAIR MTHFR PLAT
40 diabetes mellitus 29.9 ACE AGTR1 APOA1 APOB CRP MEG3
41 migraine with aura 29.9 ACE MTHFR NOTCH3
42 aortic aneurysm, familial abdominal, 1 29.9 ACE APOE CRP
43 macular degeneration, age-related, 1 29.9 APOB APOE CRP CX3CR1
44 antiphospholipid syndrome 29.9 MTHFR PLAT SELP
45 thrombophilia due to thrombin defect 29.9 CBS MTHFR PLAT
46 kidney disease 29.9 ACE ADM AGTR1 APOE CRP
47 peripheral vascular disease 29.9 ACE APOA1 APOB CRP PLAT SELP
48 coronary stenosis 29.8 ACE APOA1 APOB APOE CRP PON1
49 dementia, lewy body 29.8 ACHE APOE APP CBS
50 arteritic anterior ischemic optic neuropathy 29.8 ACE CRP MTHFR

Comorbidity relations with Cerebrovascular Disease via Phenotypic Disease Network (PDN): (show all 40)


Active Peptic Ulcer Disease Acute Cystitis
Alzheimer Disease Anxiety
Aortic Valve Disease 1 Basilar Artery Insufficiency
Benign Essential Hypertension Bronchitis
Cerebral Atherosclerosis Cerebral Degeneration
Chronic Kidney Failure Chronic Myocardial Ischemia
Decubitus Ulcer Deficiency Anemia
Encephalopathy Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Esophagitis Familial Atrial Fibrillation
Generalized Atherosclerosis Heart Disease
Hypertension, Essential Hypertensive Encephalopathy
Hypothyroidism Intermediate Coronary Syndrome
Intracranial Embolism Intracranial Thrombosis
Iron Deficiency Anemia Ischemic Heart Disease
Labyrinthitis Malignant Essential Hypertension
Mitral Valve Disease Osteoporosis
Parkinson Disease, Late-Onset Peripheral Vascular Disease
Protein-Energy Malnutrition Schizophreniform Disorder
Sinoatrial Node Disease Swallowing Disorders
Transient Cerebral Ischemia Vertebral Artery Insufficiency

Graphical network of the top 20 diseases related to Cerebrovascular Disease:



Diseases related to Cerebrovascular Disease

Symptoms & Phenotypes for Cerebrovascular Disease

UMLS symptoms related to Cerebrovascular Disease:


seizures, tremor, angina pectoris, edema, back pain, pain, chest pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, equilibration disorder, sleeplessness, transient ischemic attacks, stereotypic symptoms

GenomeRNAi Phenotypes related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 9.26 APOA1 APOB APOE SELP
2 Increased LDL uptake GR00340-A-1 8.8 APOA1 APOE SELP

MGI Mouse Phenotypes related to Cerebrovascular Disease:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.42 ACE ACHE ADM AGTR1 APOA1 APOB
2 cardiovascular system MP:0005385 10.39 ACE ADM AGTR1 APOA1 APOB APOE
3 behavior/neurological MP:0005386 10.3 ACE ACHE ADM AGTR1 APOE APP
4 growth/size/body region MP:0005378 10.3 ACE ACHE AGTR1 APOB APOE APP
5 cellular MP:0005384 10.28 ADM APOA1 APOB APOE APP COL4A1
6 immune system MP:0005387 10.26 ACE ADM AGTR1 APOB APOE APP
7 hematopoietic system MP:0005397 10.25 ACE ACHE ADM AGTR1 APOE APP
8 mortality/aging MP:0010768 10.25 ACE ACHE ADM AGTR1 APOB APOE
9 integument MP:0010771 10.11 ADM APOA1 APOE APP CX3CR1 MTHFR
10 nervous system MP:0003631 10.06 ACHE AGTR1 APOB APOE APP COL4A1
11 muscle MP:0005369 10.02 ACHE ADM APOB APOE APP COL4A1
12 liver/biliary system MP:0005370 9.98 ACE ADM APOA1 APOB APOE MTHFR
13 reproductive system MP:0005389 9.9 ACE ACHE ADM APOB APOE APP
14 renal/urinary system MP:0005367 9.86 ACE ADM AGTR1 APOE COL4A1 CX3CR1
15 respiratory system MP:0005388 9.5 ACHE ADM APOE COL4A1 NOTCH3 PLAT
16 vision/eye MP:0005391 9.28 ACHE APOB APOE COL4A1 CX3CR1 MTHFR

Drugs & Therapeutics for Cerebrovascular Disease

Drugs for Cerebrovascular Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 884)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rivastigmine Approved, Investigational Phase 4,Phase 3 123441-03-2 77991
2
Amiloride Approved Phase 4 2016-88-8, 2609-46-3 16231
3
Amlodipine Approved Phase 4,Phase 3,Phase 2,Not Applicable 88150-42-9 2162
4
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 79902-63-9 54454
5
Telmisartan Approved, Investigational Phase 4,Phase 3 144701-48-4 65999
6
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
7
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-78-2 2244
8
Ticlopidine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 55142-85-3 5472
9
Clopidogrel Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 113665-84-2, 120202-66-6 60606
10
Pantoprazole Approved Phase 4,Phase 2 102625-70-7 4679
11
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 53123-88-9 46835353 6436030 5284616
12
Everolimus Approved Phase 4,Phase 2,Phase 3,Not Applicable 159351-69-6 6442177
13
Cilostazol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 73963-72-1 2754
14
Glucosamine Approved, Investigational Phase 4,Phase 3,Not Applicable 3416-24-8 439213
15
Perindopril Approved Phase 4,Phase 3,Not Applicable 107133-36-8, 82834-16-0 107807
16
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 58-93-5 3639
17
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59729-33-8 2771
18
Candesartan cilexetil Approved Phase 4,Phase 3 145040-37-5 2540
19
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 137-58-6 3676
20
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-84-3 187
21
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 124-94-7 31307
22
Rivaroxaban Approved Phase 4,Phase 2,Phase 3,Not Applicable 366789-02-8
23
Valsartan Approved, Investigational Phase 4,Phase 2,Not Applicable 137862-53-4 60846
24
Atenolol Approved Phase 4,Phase 3 29122-68-7 2249
25
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 9005-49-6 772 46507594
26
Nadroparin Approved, Investigational Phase 4,Phase 3
27
Probucol Approved, Investigational Phase 4 23288-49-5 4912
28
Nimodipine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 66085-59-4 4497
29 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7440-66-6
31
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 94-09-7, 1994-09-7 2337
32
Acenocoumarol Approved, Investigational Phase 4,Phase 3,Not Applicable 152-72-7 9052 54676537
33
Tranexamic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1197-18-8 5526
34
Glyburide Approved Phase 4,Phase 3,Phase 2,Phase 1 10238-21-8 3488
35
Metformin Approved Phase 4,Phase 2,Not Applicable 657-24-9 14219 4091
36
Nicardipine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 55985-32-5 4474
37
alemtuzumab Approved, Investigational Phase 4 216503-57-0
38
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
39
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 6055-19-2, 50-18-0 2907
40
Azathioprine Approved Phase 4,Phase 3,Phase 2 446-86-6 2265
41
Enoxaparin Approved Phase 4,Phase 3,Phase 2,Not Applicable 9005-49-6 772
42
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
43
Donepezil Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 120014-06-4 3152
44
Bupropion Approved Phase 4,Not Applicable 34841-39-9, 34911-55-2 444
45
Varenicline Approved, Investigational Phase 4,Not Applicable 249296-44-4 5310966
46
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
47
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 113775-47-6 68602 5311068
48
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2078-54-8 4943
49
Warfarin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 81-81-2 6691 54678486
50
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 51-41-2 439260

Interventional clinical trials:

(show top 50) (show all 4961)
# Name Status NCT ID Phase Drugs
1 Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD Unknown status NCT02444637 Phase 4 Rivastigmine
2 Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive Patients Unknown status NCT01011660 Phase 4 Amlodipine, Telmisartan, Amiloride Compound , Simvastatin
3 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4 aspirin and/or clopidogrel;aspirin and/or clopidogrel
4 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4 Ginkgo Biloba Extract (GBE)
5 Prospective Multicenter Registry of Hybrid Coronary Artery Revascularization Combined With Surgical Bypass and Percutaneous Coronary Intervention Using Everolimus Eluting Metallic Stents Unknown status NCT02894255 Phase 4
6 Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection Unknown status NCT02694848 Phase 4 Salvianolate injection;Aspirin
7 Cilostazol Versus Aspirin for Primary Prevention of Atherosclerotic Events Unknown status NCT00886574 Phase 4 Cilostazol;Aspirin
8 The Impact of NBP on the Collateral Circulation in ICA/M1 Occlusion Unknown status NCT02594995 Phase 4 NBP
9 Cerebral Artery Stenosis, Coronary Artery Disease and Arrhythmia Unknown status NCT00247533 Phase 4
10 Effects of Cerebrolysin Combined With Rehabilitation on Motor Recovery in Stroke Unknown status NCT02768571 Phase 4 Cerebrolysin;Placebo
11 Effectiveness and Safety of Yiqitongluo Granule for Stroke Unknown status NCT02604654 Phase 4 Yiqitongluo granule
12 The Safety and Efficacy Study of High Dose Atorvastatin After Thrombolytic Treatment in Acute Ischemic Stroke Unknown status NCT02452502 Phase 4
13 4-point vs 4-roll Canne as Walking Aids After Stroke Unknown status NCT02279069 Phase 4
14 A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke Unknown status NCT02152280 Phase 4 Danhong Injection;Normal Saline
15 FINGER Robot Therapy Study Unknown status NCT02048826 Phase 4
16 Efficacy Study of Cilostazol and Aspirin on Cerebral Small Vessel Disease Unknown status NCT01932203 Phase 4 aspirin;cilostazol
17 Stratification of Blood Pressure Control Against Progress of Cerebral Small Vessel Diseases in Poststroke Patients Unknown status NCT01819441 Phase 4 Azelnidipine;Perindopril;hydrochlorothiazide
18 Creative Therapy to Affect Stroke Outcomes Unknown status NCT01455155 Phase 4
19 Assess the Penumbra System in the Treatment of Acute Stroke Unknown status NCT01429350 Phase 4 intravenous (IV) recombinant human tissue plasminogen activator (rtPA)
20 Effects on Clinical and Functional Outcome of Escitalopram in Adult Stroke Patients Unknown status NCT00967408 Phase 4 Escitalopram;Placebo
21 Functional Electrical Stimulation (FES) Assisted Walking: Enhancement of Walking Function After Stroke Unknown status NCT00552916 Phase 4
22 Early Warning and Optimization Strategy in Carotid Endarterectomy Unknown status NCT01210937 Phase 4
23 Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST) Unknown status NCT00108706 Phase 4 Candesartan
24 Preventive Effects of Ginseng Against Atherosclerosis Unknown status NCT02796664 Phase 4
25 Botulinum Toxin A for Shoulder Pain After Stroke Unknown status NCT02618603 Phase 4 Botulinum toxin A;Triamcinolone Acetonide
26 Comprehensive Reparative Therapy in Ischemic Stroke COMplex Repair in Ischemic Stroke-Arm Unknown status NCT02581371 Phase 4 Cerebrolysin infusion
27 Evaluation of WATCHMAN Left Atrial Appendage Occlusion Device in Patients With Atrial Fibrillation Versus Rivaroxaban Unknown status NCT02549963 Phase 4 Rivaroxaban
28 The Effectiveness of Early Botulinum Toxin A Injection for Lower Limbs Spasticity in Subacute Stroke Adults Unknown status NCT02505802 Phase 4 BoNT-A injection
29 Intensive Statin Treatment in Acute Ischemic Stroke Patients With INtracranial Atherosclerosis Unknown status NCT02458755 Phase 4 High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg
30 Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol Unknown status NCT02403349 Phase 4 Fimasartan;Valsartan;Atenolol
31 Optimal Dose of Extracorporeal Shock Wave Therapy After Botulinum Toxin Type A Injection for Post-stroke Spasticity Unknown status NCT02358005 Phase 4
32 Rectus Femoris Tenotomy Versus Botulinum Toxin A for Stiff Knee Gait After Stroke Unknown status NCT02114736 Phase 4 Botulinum Toxin injection in the rectus femoris muscle
33 Safety Study of Melatonin in Stroke Patients Unknown status NCT01863277 Phase 4 Melatonin;placebo
34 Safety and Efficacy of Heparin and Nadroparin in the Acute Phase of Ischemic Stroke Unknown status NCT01862978 Phase 4 Heparin;Nadroparin;Placebo
35 Efficacy Study of Huatuo Zaizao Pills in Improving of Neural Function in Acute Ischemic Stroke Unknown status NCT01758536 Phase 4 Huatuo Zaizao Pills
36 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Astragalus Membranaceus in the Patients After Stroke With Fatigue Unknown status NCT01554787 Phase 4 Chinese Herb Astragalus membranaceus
37 PreventIon of IMT Progression in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage-IMT Study Unknown status NCT02483169 Phase 4 cilostazol;Probucol;Aspirin;placebo of cilostazol;Placebo of aspirin
38 Efficacy and Safety Study of Nimodipine to Prevent Mild Cognitive Impairment After Acute Ischemic Strokes Unknown status NCT01220622 Phase 4 Nimodipine;Placebo
39 Sleep Disordered Breathing in Transient Ischemic Attack (TIA)/Ischemic Stroke and Continuous Positive Airway Pressure (CPAP) Treatment Efficacy Unknown status NCT01097967 Phase 4
40 Valsartan Efficacy on Modest Blood Pressure Reduction in Acute Ischemic Stroke Unknown status NCT00874601 Phase 4 Diovan® (valsartan)
41 Comparison of Two Strategies for Glycemic Control in Acute Ischemic Stroke Unknown status NCT00747279 Phase 4 Intensive insulin therapy
42 The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial Unknown status NCT00724724 Phase 4 Butylphthalide Soft Capsules;Aspirin
43 Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting Unknown status NCT01572623 Phase 4 Clopidogrel;Atorvastatin
44 Comparison of Staged Angioplasty and Routine Single-stage Stenting (CAS) in the Treatment of Carotid Artery Stenosis Unknown status NCT02224209 Phase 4
45 The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic Attack Unknown status NCT02144831 Phase 4 anti-thrombotic treatment using Aspirin (ASA 75-325mg) and Clopidogrel (75mg)
46 PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage Unknown status NCT01013532 Phase 4 Cilostazol;Probucol;Aspirin;placebo of cilostazol;placebo of aspirin
47 Clinical Re-evaluation of Removing Blood Stasis Therapy in Treating Acute Cerebral Hemorrhage Safety and Efficacy Unknown status NCT01918722 Phase 4 ICH-1(herbal medicine with Hirudo, Tabanus);placebo;ICH-2(herbal medicine without Hirudo, Tabanus)
48 Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography (RETORIC) Unknown status NCT02826200 Phase 4 Acenocoumarol
49 The Role of Statins in Preventing Cerebral Vasospasm Secondary to Subarachnoid Hemorrhage Unknown status NCT01346748 Phase 4 statin
50 A Study on the Safety of Tranexamic Acid for the Chronic Subdural Hematoma Population Unknown status NCT02618382 Phase 4 Tranexamic Acid

Search NIH Clinical Center for Cerebrovascular Disease

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: stroke

Genetic Tests for Cerebrovascular Disease

Anatomical Context for Cerebrovascular Disease

MalaCards organs/tissues related to Cerebrovascular Disease:

41
Brain, Heart, Endothelial, Testes, Kidney, Liver, Pituitary

Publications for Cerebrovascular Disease

Articles related to Cerebrovascular Disease:

(show top 50) (show all 1320)
# Title Authors Year
1
Lenalidomide-Induced Ischemic Cerebrovascular Disease in Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome. ( 29395638 )
2018
2
Statin prescription rates and their facility-level variation in patients with peripheral artery disease and ischemic cerebrovascular disease: Insights from the Department of Veterans Affairs. ( 29600737 )
2018
3
Prevalence, Risk Factors, Outcomes, and Treatment of Obstructive Sleep Apnea in Patients with Cerebrovascular Disease: A Systematic Review. ( 29555400 )
2018
4
Under-utilization of statin medications in patients with peripheral artery disease or cerebrovascular disease. ( 29600738 )
2018
5
Cerebrovascular Disease Knowledge Portal: An Open-Access Data Resource to Accelerate Genomic Discoveries in Stroke. ( 29335331 )
2018
6
Systematic investigation of the Erigeron breviscapus mechanism for treating cerebrovascular disease. ( 29783016 )
2018
7
Association between primary SjAPgren's syndrome, cardiovascular and cerebrovascular disease: a systematic review and meta-analysis. ( 29600936 )
2018
8
Revascularization experience and results in ischaemic cerebrovascular disease: Moyamoya disease and carotid occlusion. ( 29550248 )
2018
9
Improvement of postoperative cognitive dysfunction and attention network function of patients with ischemic cerebrovascular disease via dexmedetomidine. ( 29599834 )
2018
10
Brain amyloid burden and cerebrovascular disease are synergistically associated with neurometabolism in cognitively unimpaired older adults. ( 29310864 )
2018
11
The effect of rheumatoid arthritis on the risk of cerebrovascular disease and coronary artery disease in young adults. ( 29861211 )
2018
12
Controversies in cerebrovascular disease: High or low doses of recombinant tissue plasminogen activator to treat acute stroke? A literature review. ( 29891335 )
2018
13
Association Between Heart Rate and Subclinical Cerebrovascular Disease in the Elderly. ( 29284731 )
2018
14
High-resolution Imaging of Myeloperoxidase Activity Sensors in Human Cerebrovascular Disease. ( 29769642 )
2018
15
Survival after in-hospital cardiac arrest among cerebrovascular disease patients. ( 29789199 )
2018
16
Migraine and cerebrovascular disease: still a dangerous connection? ( 29904830 )
2018
17
More Than Meets the Eye: Cerebrovascular Disease in Sickle Cell Disease Is About More Than Sickling. ( 29695469 )
2018
18
Motor function declines over time in human immunodeficiency virus and is associated with cerebrovascular disease, while HIV-associated neurocognitive disorder remains stable. ( 29696578 )
2018
19
Impact of Clopidogrel Therapy on Mortality and Cancer in Patients With Cardiovascular and Cerebrovascular Disease: A Patient-Level Meta-Analysis. ( 29311290 )
2018
20
Preeclampsia Increases the Incidence of Postpartum Cerebrovascular Disease in Korean Population. ( 29349936 )
2018
21
Cognitive deterioration in schizophrenia: aging and cerebrovascular disease. ( 29936917 )
2018
22
Lower body functioning and correlates among older American Indians: The Cerebrovascular Disease and Its Consequences in American Indians Study. ( 29304750 )
2018
23
Outcomes After Percutaneous Coronary Intervention in Patients With a History of Cerebrovascular Disease: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium. ( 29895601 )
2018
24
The effect of demographic features on aortic arch anatomy and its role in the etiology of cerebrovascular disease. ( 29302189 )
2018
25
On the Reproducibility of Inversion Recovery Intravoxel Incoherent Motion Imaging in Cerebrovascular Disease. ( 29217741 )
2018
26
Comparison of Blood Oxygenation Level-Dependent fMRI and Provocative DSC Perfusion MR Imaging for Monitoring Cerebrovascular Reserve in Intracranial Chronic Cerebrovascular Disease. ( 29371256 )
2018
27
PET imaging of the neurovascular interface in cerebrovascular disease. ( 29611539 )
2018
28
Regional Subclinical Cerebrovascular Disease Is Associated with Balance in an Elderly Multi-Ethnic Population. ( 29953989 )
2018
29
Sir Winston Churchill: cerebrovascular disease January 1950-March 1952. ( 29932355 )
2018
30
Functional Trajectories, Cognition, and Subclinical Cerebrovascular Disease. ( 29374104 )
2018
31
Use of cardiovascular polypills for the secondary prevention of cerebrovascular disease. ( 29325730 )
2018
32
Haploidentical stem cell transplantation cures autoimmune hepatitis and cerebrovascular disease in a patient with sickle cell disease. ( 29335630 )
2018
33
Subclinical cerebrovascular disease in NAFLD without overt risk factors for atherosclerosis. ( 29175651 )
2018
34
MicroRNA-132 modifies angiogenesis in patients with ischemic cerebrovascular disease by suppressing the NF‑κB and VEGF pathway. ( 29207094 )
2018
35
Sickle cell disease: a malady beyond a hemoglobin defect in cerebrovascular disease. ( 29207881 )
2018
36
Moyamoya-like cerebrovascular disease in a child with a novel mutation in myosin heavy chain 11. ( 29263223 )
2018
37
Effect of polydatin on expression of p53 and Notch1 in brain tissue of ischemic cerebrovascular disease. ( 29504377 )
2018
38
Relationship Between Antipsychotic Medications and Cerebrovascular Disease in Patients With Serious Mental Illness. ( 29509176 )
2018
39
The numerical study on specialized treatment strategies of enhanced external counterpulsation for cardiovascular and cerebrovascular disease. ( 29713856 )
2018
40
Etiology of acute ischaemic cerebrovascular disease associated with rheumatoid arthritis: changes with progression of anti-inflammatory therapy. ( 29995999 )
2018
41
Neurosurgical Management and Outcomes of Cerebrovascular Disease in Pediatric Patients with Heart Disease. ( 29998935 )
2018
42
Relationship between cerebral microbleeds location and cognitive impairment in patients with ischemic cerebrovascular disease. ( 30004994 )
2018
43
Complex disease management of pregnant young patient with familial hypercholesterolaemia complicated by coronary artery disease and cerebrovascular disease. ( 30017729 )
2018
44
Neuroimaging and neuropathology indices of cerebrovascular disease burden: A systematic review. ( 30021917 )
2018
45
Asymptomatic Cerebrovascular Disease in Dialysis Patients. ( 30041200 )
2018
46
Case-control study examining the association between allopurinol use and ischemic cerebrovascular disease. ( 30042112 )
2018
47
Assessment of risk factors for cerebrovascular disease among the elderly in Beijing: A 23-year community-based prospective study in China. ( 30096587 )
2018
48
The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease. ( 30100558 )
2018
49
Association of pseudoexfoliation syndrome with cardiovascular and cerebrovascular disease: a systematic review and meta-analysis. ( 30119791 )
2018
50
Cerebrovascular disease influences functional and structural network connectivity in patients with amnestic mild cognitive impairment and Alzheimer's disease. ( 30121086 )
2018

Variations for Cerebrovascular Disease

Expression for Cerebrovascular Disease

Search GEO for disease gene expression data for Cerebrovascular Disease.

Pathways for Cerebrovascular Disease

Pathways related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.41 APOA1 APOB APOE MTHFR MTR
2
Show member pathways
11.72 APP COL4A1 CX3CR1 PLAT
3
Show member pathways
11.57 APOA1 APOB APOE COL4A1
4
Show member pathways
11.56 APOA1 APOB APOE CBS CRP MTHFR
5 11.23 APOB PLAT SELP
6 10.76 ACE APOE APP CX3CR1
7 10.69 ACE APP PLAT
8 10.54 HOTAIR MEG3
9 10.34 CBS MTHFR

GO Terms for Cerebrovascular Disease

Cellular components related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.93 ACE ACHE ADM APOA1 APOB APOE
2 endoplasmic reticulum lumen GO:0005788 9.85 APOA1 APOB APOE APP COL4A1
3 collagen-containing extracellular matrix GO:0062023 9.84 APOA1 APOE COL4A1 PLAT
4 early endosome GO:0005769 9.81 APOA1 APOB APOE APP
5 high-density lipoprotein particle GO:0034364 9.61 APOA1 APOE PON1
6 very-low-density lipoprotein particle GO:0034361 9.58 APOA1 APOB APOE
7 endosome lumen GO:0031904 9.55 APOB APP
8 endocytic vesicle lumen GO:0071682 9.54 APOA1 APOB APOE
9 synaptic cleft GO:0043083 9.52 ACHE APOE
10 low-density lipoprotein particle GO:0034362 9.5 APOA1 APOB APOE
11 spherical high-density lipoprotein particle GO:0034366 9.49 APOA1 PON1
12 discoidal high-density lipoprotein particle GO:0034365 9.48 APOA1 APOE
13 chylomicron GO:0042627 9.43 APOA1 APOB APOE
14 extracellular space GO:0005615 9.4 ACE ACHE ADM APOA1 APOB APOE
15 intermediate-density lipoprotein particle GO:0034363 9.13 APOA1 APOB APOE

Biological processes related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.9 APOA1 APOB APOE APP
2 cholesterol homeostasis GO:0042632 9.82 APOA1 APOB APOE
3 response to wounding GO:0009611 9.79 ACHE ADM CX3CR1
4 retinoid metabolic process GO:0001523 9.73 APOA1 APOB APOE
5 triglyceride catabolic process GO:0019433 9.67 APOA1 APOB APOE
6 high-density lipoprotein particle remodeling GO:0034375 9.66 APOA1